Robert Wood Johnson Medical School Hematology and Medical Oncology

Topics

• Lymphoma Diagnosis and Treatment 242
• Multiple Myeloma Research and Treatments 84
• Chronic Lymphocytic Leukemia Research 68
• Acute Myeloid Leukemia Research 66
• CAR-T cell therapy research 50
• Hematopoietic Stem Cell Transplantation 44
• Monoclonal and Polyclonal Antibodies Research 43
• Prostate Cancer Treatment and Research 26
• Breast Cancer Treatment Studies 22
• CNS Lymphoma Diagnosis and Treatment 22
• Platelet Disorders and Treatments 19
• Cancer Immunotherapy and Biomarkers 17

Most cited

1. Polatuzumab Vedotin in Previously Untreated Diffuse Large B-Cell Lymphoma.

   The New England journal of medicine · 2022 · 793 citations · Matthew Matasar

2. Nivolumab+AVD in Advanced-Stage Classic Hodgkin's Lymphoma.

   The New England journal of medicine · 2024 · 205 citations · Andrew Evens

3. Safety and efficacy of mosunetuzumab, a bispecific antibody, in patients with relapsed or refractory follicular lymphoma: a single-arm, multicentre, phase 2 study.

   The Lancet. Oncology · 2022 · 398 citations · Matthew Matasar

4. Linvoseltamab for Treatment of Relapsed/Refractory Multiple Myeloma.

   Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2024 · 152 citations · Mansi Shah

5. Overall Survival with Brentuximab Vedotin in Stage III or IV Hodgkin's Lymphoma.

   The New England journal of medicine · 2022 · 293 citations · Andrew Evens

6. Pirtobrutinib after a Covalent BTK Inhibitor in Chronic Lymphocytic Leukemia.

   The New England journal of medicine · 2023 · 204 citations · Joanna Rhodes

7. Single-Agent Mosunetuzumab Shows Durable Complete Responses in Patients With Relapsed or Refractory B-Cell Lymphomas: Phase I Dose-Escalation Study.

   Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2022 · 285 citations · Matthew Matasar

8. Real-world application of tumor mutational burden-high (TMB-high) and microsatellite instability (MSI) confirms their utility as immunotherapy biomarkers.

   ESMO open · 2022 · 289 citations · Tina Mayer